The Maverick ENA 4 and ENA 6 assay kits, which are designed for use on the company’s Maverick Detection system, simultaneously screen several autoantibodies found in autoimmune connective tissue disorders including systemic lupus erythematosus (SLE).

The Maverick ENA 4 assay tests for the presence of four commonly measured extractable nuclear antigens (ENA) including SS-A, SS-B, Sm and RNP, while the Maverick ENA 6 assay tests for two additional commonly measured antigens including Scl-70 and Jo-1.

By using very small volume samples from a variety of matrices including serum and plasma, the assays’ one-step workflow delivers results in 15 minutes.

The assays, which are available to participants in Genalyte’s Early Access program, enables scientists to gain pre-launch access to multiplexed autoantibody assays and the silicon photonics-based Maverick detection system.

Genalyte CEO Cary Gunn said the company is also developing a number of assays for autoimmune diseases including rheumatoid arthritis, celiac disease and others.

"The Maverick Early Access program generated considerable interest at recent immunology meetings, and we look forward to working with our Early Access collaborators as they put the Maverick Detection system to work in their labs," Gunn added.

The company said Maverick ENA 4 and ENA 6 Assays are currently available for research use only.